ICCM

IceCure Medical Ltd. · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website icecure-medical.com
Employees(FY) 65
ISIN IL0011224156

Performance

+1.61%

+14.55%

+49.11%

+72.84%

+14.55%

YTD

-8.7%

Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Advanced Technical Analysis

Technical Analysis of ICCM 2025-01-31

The stock exhibits a strong bullish sentiment with a Moving Average Score of 90 and a Technical Score of 89, indicating robust upward momentum. However, the Oscillators Score of 50 suggests a neutral stance, implying that while the overall trend is positive, there may be some consolidation or indecision in the short term.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ICCM

Stock Rank

Recent News & Updates

2025-01-27 18:43
IceCure submits application to Chinas NMPA for cryoablation system approval(Yahoo Finance)
2025-01-26 19:30
IceCure Files for Regulatory Approval of ProSense Cryoablation System in China(Prnewswire)
2025-01-12 18:00
IceCure Medical CEO Issues Letter to Shareholders and Reports Increase of 42% in ProSense Sales for 2024 in North America(Prnewswire)
2025-01-12 18:00
IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America(Yahoo Finance)
2025-01-05 19:30
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule(Prnewswire)
2025-01-02 19:30
European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology(Prnewswire)
2024-12-15 19:30
Data on IceCure's ProSense Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting(Prnewswire)
2024-12-04 19:30
IceCure's ProSense Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results(Prnewswire)
2024-11-25 20:40
IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates(Yahoo Finance)
2024-11-25 19:30
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense Cryoablation(Prnewswire)
2024-11-24 19:30
IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office(Prnewswire)
2024-11-19 19:30
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024(Yahoo Finance)
2024-11-19 19:30
IceCure Medical to Report Third Quarter 2024 Financial and Operational Results on November 26, 2024(Prnewswire)
2024-11-18 19:30
IceCure's ProSense Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health(Prnewswire)
2024-11-10 17:35
IceCures cryoablation system for breast cancer treatment gains FDA panel support(Yahoo Finance)
2024-11-07 18:00
FDA Advisory Panel Votes in Favor of IceCure's ProSense Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer(Prnewswire)
2024-10-28 20:30
Upcoming FDA Advisory Panel for IceCure's ProSense Marketing Authorization Receives Large Number of Public Comments from Stakeholders(Prnewswire)
2024-10-20 20:30
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System(Prnewswire)
2024-10-06 20:15
IceCure's ProSense Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference(Prnewswire)
2024-09-23 20:15
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate(Prnewswire)
2024-09-15 20:00
Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues(Prnewswire)
2024-09-11 20:00
IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024(Prnewswire)
2024-09-03 20:30
IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences(Prnewswire)
2024-08-27 20:30
USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies(Prnewswire)
2024-08-20 00:52
ICCM Stock Earnings: Icecure Medical Beats EPS, Beats Revenue for Q2 2024(Investorplace)
2024-08-19 21:40
IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates(Yahoo Finance)
2024-08-19 20:30
IceCure Medical Reports 20% Growth in ProSense System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets(Prnewswire)
2024-08-13 20:30
IceCure's ProSense Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery(Prnewswire)
2024-08-12 20:30
IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024(Prnewswire)
2024-08-06 20:30
IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: 'Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials'(Prnewswire)

Page 1 of 6

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.